Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
Objectives Tumor mutational burden is an emerging biomarker of response to immune
checkpoint inhibitors (ICI), whose clinical adoption is challenging. We hypothesized that …
checkpoint inhibitors (ICI), whose clinical adoption is challenging. We hypothesized that …
Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients
TJ Jensen, AM Goodman, S Kato, CK Ellison… - Molecular cancer …, 2019 - AACR
Inhibitors of the PD-1/PD-L1/CTLA-4 immune checkpoint pathway have revolutionized
cancer treatment. Indeed, some patients with advanced, refractory malignancies achieve …
cancer treatment. Indeed, some patients with advanced, refractory malignancies achieve …
[HTML][HTML] Regulatory implications of ctDNA in immuno-oncology for solid tumors
PJ Vellanki, S Ghosh, A Pathak, MJ Fusco… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …
minimally invasive approach for the diagnosis and management of patients with cancer and …
[HTML][HTML] Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non–small cell lung cancer
B Pellini, RW Madison, MA Childress, ST Miller… - Clinical Cancer …, 2023 - AACR
Purpose: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …
driver-negative non–small cell lung cancer (NSCLC), with maintenance therapy given after …
[HTML][HTML] Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
L Sivapalan, JC Murray, JVL Canzoniero… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …
and provide unique insights into the evolving molecular landscape of cancers under the …
Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy
Purpose: We evaluated the predictive value of pretreatment ctDNA to inform therapeutic
outcomes in patients with metastatic melanoma relative to type and line of treatment …
outcomes in patients with metastatic melanoma relative to type and line of treatment …
Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumors
A Pender, E Titmuss, ED Pleasance, KY Fan… - Clinical Cancer …, 2021 - AACR
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid
tumors with dramatic and durable responses seen across multiple tumor types. However …
tumors with dramatic and durable responses seen across multiple tumor types. However …
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …
[HTML][HTML] ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
V Anagnostou, C Ho, G Nicholas, RA Juergens… - Nature medicine, 2023 - nature.com
Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …
immunotherapy. BR. 36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of …
ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy
PURPOSE Identification of predictors for overall survival (OS) allows timely detection of
clinical efficacy signals and therefore facilitates treatment decisions. We assessed the …
clinical efficacy signals and therefore facilitates treatment decisions. We assessed the …